Therefore, in our clinical work, after measuring the NLRP1 expression level in the surgical specimens of LUAD patients, we can use it to evaluate the malignancy of tumor, predict the prognosis of patient, assess the status of immune microenvironment in tumor tissue, and even develop immunotherapeutic drugs targeting NLRP1, which has been verified to be a right direction: DAC (5-aza-2-deoxycytidine), an antitumor drug, can restore the NLRP1 expression level to suppress the growth of colon cancer [21]. The gene discussed is NLRP1; the disease is neoplasm.